Clinical Trial Update: NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression [Phase 3]

View source ↗

Summary

Phase 3 trial update for NRX100 versus placebo aiming to rapidly stabilize acute suicidal ideation and behavior in bipolar depression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression
• Suicidal Ideation

Drugs mentioned

• NRX100

Snippet

Sponsor: NeuroRx, Inc. | Conditions: Bipolar Depression, Suicidal Ideation | Phase 3 | Status: UNKNOWN